MART-10, a new generation of vitamin d analog, is more potent than 1 α,25-dihydroxyvitamin Din inhibiting cell proliferation and inducing apoptosis in ER+ MCF-7 breast cancer cells

Evidence-based Complementary and Alternative Medicine

Volumn 2012, Issue , 2012, Pages

  Chiang, Kun Chun ^a,b   Yeh, Chun Nan ^a   Chen, Shin Cheh ^a   Shen, Shih Che ^a   Hsu, Jun Te ^a   Yeh, Ta Sen ^a   Pang, Jong Hwei S ^b   Su, Li Jen ^c   Takano, Masashi ^d   Kittaka, Atsushi ^d   Juang, Horng Heng ^b   Chen, Tai C ^e  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c NATIONAL CENTRAL UNIVERSITY   (Taiwan)

^d TEIKYO UNIVERSITY   (Japan)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

19 NOR 2ALPHA (3 HYDROXYPROPYL) 1ALPHA,25 DIHYDROXYVITAMIN D3; CALCITRIOL; CYTOCHROME C; MART 10; PROTEIN BAX; PROTEIN P21; PROTEIN P27; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOSOL; ENZYME RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRION; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84872141042     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2012/310872     Document Type: Article

References (44)

1. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D., Global cancer statistics. CA Cancer Journal for Clinicians 2011 61 2 69 90 2-s2.0-79952232216 10.3322/caac.20107
2. Zwart W., Theodorou V., Carroll J. S., Estrogen receptor-positive breast cancer: a multidisciplinary challenge. Wiley Interdisciplinary Reviews. Systems Biology and Medicine 2011 3 2 216 230 10.1002/wsbm.109
3. Holm C., Kok M., Michalides R., Fles R., Koornstra R. H. T., Wesseling J., Hauptmann M., Neefjes J., Peterse J. L., Stål O., Landberg G., Linn S. C., Phosphorylation of the oestrogen receptor α at serine 305 and prediction of tamoxifen resistance in breast cancer. Journal of Pathology 2009 217 3 372 379 2-s2.0-60549097403 10.1002/path.2455
4. Krishnan A. V., Swami S., Feldman D., The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer. Steroids 2012 77 11 1107 1112 10.1016/j.steroids.2012.06.005
5. Fleet J. C., DeSmet M., Johnson R., Li Y., Vitamin D and cancer: a review of molecular mechanisms. Biochemical Journal 2012 441 1 61 76 10.1042/BJ20110744
6. Chiang K. C., Chen T. C., Vitamin D for the prevention and treatment of pancreatic cancer. World Journal of Gastroenterology 2009 15 27 3349 3354 2-s2.0-70349578361 10.3748/wjg.15.3349
7. Chiang K. C., Yeh C. N., Chen M. F., Chen T. C., Hepatocellular carcinoma and vitamin D: a review. Journal of Gastroenterology and Hepatology 2011 26 11 1597 1603 10.1111/j.1440-1746.2011.06892.x
8. Ylikomi T., Laaksi I., Lou Y. R., Martikainen P., Miettinen S., Pennanen P., Purmonen S., Syvälä H., Vienonen A., Tuohimaam P., Antiproliferative Action of Vitamin D. Vitamins and Hormones 2002 64 357 406 2-s2.0-18244413307 (Pubitemid 135763169)
9. Chiang K. C., Chen T. C., The anti-cancer actions of vitamin D. Anti-Cancer Agents in Medicinal Chemistry 2012 13 126 139
10. Krishnan A. V., Feldman D., Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annual Review of Pharmacology and Toxicology 2011 51 311 336 2-s2.0-79952001956 10.1146/annurev-pharmtox-010510- 100611
11. 3 (MART-10) is a potent cell growth regulator with enhanced chemotherapeutic potency in liver cancer cells. Steroids 2011 76 13 1513 1519
12. Welsh J., Cellular and molecular effects of vitamin D on carcinogenesis. Archives of Biochemistry and Biophysics 2012 523 1 107 114
13. Deeb K. K., Trump D. L., Johnson C. S., Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature Reviews Cancer 2007 7 9 684 700 2-s2.0-34548202165 10.1038/nrc2196 (Pubitemid 47327412)
14. 3 on liver cancer cells. Anticancer Research 2009 29 9 3591 3596 2-s2.0-68549092570
15. Chen T. C., Holick M. F., Vitamin D and prostate cancer prevention and treatment. Trends in Endocrinology and Metabolism 2003 14 9 423 430 2-s2.0-0242612058 10.1016/j.tem.2003.09.004 (Pubitemid 37392215)
16. Bouillon R., Verstuyf A., Verlinden L., Allewaert K., Branisteanu D., Mathieu C., Van Baelen H., Non-hypercalcemic pharmacological aspects of vitamin D analogs. Biochemical Pharmacology 1995 50 5 577 583 2-s2.0-0029080966 10.1016/0006-2952(95)00121-F
17. Guyton K. Z., Kensler T. W., Posner G. H., Cancer chemoprevention using natural vitamin D and synthetic analogs. Annual Review of Pharmacology and Toxicology 2001 41 421 442 2-s2.0-0035035190 10.1146/annurev.pharmtox.41.1.421 (Pubitemid 32385894)
18. Brown A. J., Slatopolsky E., Vitamin D analogs: therapeutic applications and mechanisms for selectivity. Molecular Aspects of Medicine 2008 29 6 433 452 2-s2.0-56049110628 10.1016/j.mam.2008.04.001
19. Bower M., Colston K. W., Stein R. C., Hedley A., Gazet J. C., Ford H. T., Coombes R. C., Topical calcipotriol treatment in advanced breast cancer. Lancet 1991 337 8743 701 702 2-s2.0-0025980581 10.1016/0140-6736(91)90280-3
20. Gulliford T., English J., Colston K. W., Menday P., Moller S., Coombes R. C., A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. British Journal of Cancer 1998 78 1 6 13 2-s2.0-0031806849 (Pubitemid 28276762)
21. 3 with Julia olefination: high potency in induction of differentiation on HL-60 cells. Journal of Organic Chemistry 2003 68 19 7407 7415 2-s2.0-10744233576 (Pubitemid 37122492)
22. 3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Research 2009 29 9 3547 3553 2-s2.0-68549092572
23. 3 with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells. Journal of Steroid Biochemistry and Molecular Biology 2011 127 3-5 269 275
24. 3 analogs as therapeutic agents for prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 2007 103 3-5 717 720 2-s2.0-33947187323 10.1016/j.jsbmb.2006.12.009 (Pubitemid 46401314)
25. Ouyang W., Ma Q., Li J., Zhang D., Liu Z. G., Rustgi A. K., Huang C., Cyclin D1 induction through I B kinase β /nuclear factor- B pathway is responsible for arsenite-induced increased cell cycle G 1-S phase transition in human keratinocytes. Cancer Research 2005 65 20 9287 9293 2-s2.0-27144482083 10.1158/0008-5472.CAN-05-0469 (Pubitemid 41507995)
26. Vermes I., Haanen C., Reutelingsperger C., Flow cytometry of apoptotic cell death. Journal of Immunological Methods 2000 243 1-2 167 190 2-s2.0-0034699433 10.1016/S0022-1759(00)00233-7
27. Darzynkiewicz Z., Galkowski D., Zhao H., Analysis of apoptosis by cytometry using TUNEL assay. Methods 2008 44 3 250 254 2-s2.0-39749163470 10.1016/j.ymeth.2007.11.008 (Pubitemid 351296445)
28. Buras R. R., Schumaker L. M., Davoodi F., Brenner R. V., Shabahang M., Nauta R. J., Evans S. R. T., Vitamin D receptors in breast cancer cells. Breast Cancer Research and Treatment 1994 31 2-3 191 202 2-s2.0-0028114713 10.1007/BF00666153 (Pubitemid 24323461)
29. Jaruga E., Salvioli S., Dobrucki J., Chrul S., Bandorowicz-Pikuła J., Sikora E., Franceschi C., Cossarizza A., Bartosz G., Apoptosis-like, reversible changes in plasma membrane asymmetry and permeability, and transient modifications in mitochondrial membrane potential induced by curcumin in rat thymocytes. FEBS Letters 1998 433 3 287 293 2-s2.0-0032555342 (Pubitemid 128369980)
30. 3 a novel vitamin D-related compound with potential therapeutic activity. Tetrahedron Letters 1990 31 13 1823 1824 2-s2.0-0025228936 10.1016/S0040-4039(00)98795-1 (Pubitemid 20106899)
31. 3 with selected 2 α -substituted analogues. Journal of Medicinal Chemistry 2006 49 17 5199 5205 2-s2.0-33747452055 10.1021/jm0604070 (Pubitemid 44260215)
32. 3 analogues and their docking to vitamin D receptors. Journal of Organic Chemistry 2001 66 26 8760 8771 2-s2.0-0035966193 10.1021/jo010375i (Pubitemid 34042239)
33. Lopes N., Sousa B., Martins D., Gomes M., Vieira D., Veronese L. A., Milanezi F., Paredes J., Costa J. L., Schmitt F., Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions Vitamin D pathways unbalanced in breast lesions. BMC Cancer 2010 10 483 2-s2.0-77956478256 10.1186/1471-2407-10-483
34. Chen W. Y., Bertone-Johnson E. R., Hunter D. J., Willett W. C., Hankinson S. E., Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiology Biomarkers and Prevention 2005 14 10 2335 2339 2-s2.0-26444435877 10.1158/1055-9965.EPI-05-0283 (Pubitemid 41437833)
35. 3 on the G1-S phase-controlling machinery. Molecular Endocrinology 2001 15 8 1370 1380 2-s2.0-0034742488 10.1210/me.15.8.1370 (Pubitemid 32703484)
36. 3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Research and Treatment 1997 42 1 31 41 2-s2.0-0031031951 10.1023/A:1005772432465 (Pubitemid 27056726)
37. Reed J. C., Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Seminars in Hematology 1997 34 4 supplement 5 9 19 2-s2.0-0031464448 (Pubitemid 28032415)
38. 3 and its analogues on induction of apoptosis in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 1996 58 4 395 401 2-s2.0-0030199843 10.1016/0960-0760(96)00048-9 (Pubitemid 26348973)
39. 3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 1996 58 4 367 376 2-s2.0-0030200377 10.1016/0960-0760(96)00055-6 (Pubitemid 26348970)
40. Boatright K. M., Salvesen G. S., Mechanisms of caspase activation. Current Opinion in Cell Biology 2003 15 6 725 731 2-s2.0-0344309002 10.1016/j.ceb.2003.10.009 (Pubitemid 37492933)
41. Narvaez C. J., Welsh J., Role of Mitochondria and Caspases in Vitamin D-mediated Apoptosis of MCF-7 Breast Cancer Cells. Journal of Biological Chemistry 2001 276 12 9101 9107 2-s2.0-0035937751 10.1074/jbc.M006876200
42. Jänicke R. U., Sprengart M. L., Wati M. R., Porter A. G., Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. Journal of Biological Chemistry 1998 273 16 9357 9360 2-s2.0-0040298568 10.1074/jbc.273.16.9357 (Pubitemid 28183012)
43. Krishnan A. V., Swami S., Peng L., Wang J., Moreno J., Feldman D., Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology 2010 151 1 32 42 2-s2.0-73649116021 10.1210/en.2009-0855
44. 3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clinical Cancer Research 2000 6 8 3371 3379 2-s2.0-0033624178 (Pubitemid 30637769)